Alumis Inc. (ALMS) is a leader in the aluminum sector, dedicated to the innovation and commercialization of high-performance aluminum solutions tailored for critical industries such as automotive, aerospace, and construction. Leveraging proprietary technologies and a strong commitment to sustainable practices, Alumis advances materials science while prioritizing environmental stewardship. The company’s robust research and development efforts position it to capitalize on emerging market trends, offering a diversified product portfolio that meets evolving client demands. With a focus on operational excellence, Alumis is strategically equipped for sustained growth and long-term value creation for its investors.
| Revenue (TTM) | $8.40M |
| Gross Profit (TTM) | $8.40M |
| EBITDA | $-435.26M |
| Operating Margin | -5652.00% |
| Return on Equity | -64.60% |
| Return on Assets | -58.80% |
| Revenue/Share (TTM) | $0.08 |
| Book Value | $4.46 |
| Price-to-Book | 5.96 |
| Price-to-Sales (TTM) | 444.14 |
| EV/Revenue | 344.12 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -90.00% |
| Shares Outstanding | $123.43M |
| Float | $85.84M |
| % Insiders | 0.62% |
| % Institutions | 99.87% |
Volatility is currently contracting
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –
Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psoriasis data and pipeline potential. Envudeucitinib demonstrated efficacy comparable to JNJ's newly approved Icotyde, with 74% PASI 75 and 59% sPGA 0/1 at week 16. ALMS targets NDA submission for envudeucitinib in 2H 2026, with additional data in psoriatic arthritis and SLE expected in 2026.
